Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
| Application |
Dilution |
| 1:500-1:3000 |
| 1:100-1:1000 |
Not tested in other applications.
Calculated MW
Positive Control
TL1 , mouse lung , Rat spleen , U87-MG conditioned medium
Predict Reactivity
Bovine, Rhesus Monkey(>80% identity)
Form
Liquid
Buffer
1XPBS, 20% Glycerol (pH7). 0.025% ProClin 300 was added as a preservative.
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
0.93mg/ml(Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Recombinant protein encompassing a sequence within the center region of human VEGFC. The exact sequence is proprietary.
Purification
Purified by antigen-affinity chromatography.
Conjugation
Unconjugated
Note
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Synonyms
Flt4-L antibody, VRP antibody, VEGFC antibody, vascular endothelial growth factor-related protein antibody, VEGF-C antibody, FLT4 ligand DHM antibody, vascular endothelial growth factor C antibody
Cellular Localization
Secreted
Background
The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family, is active in angiogenesis and endothelial cell growth, and can also affect the permeability of blood vessels. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-3 receptors. Only the fully processed form can bind and activate VEGFR-2 receptors. This protein is structurally and functionally similar to vascular endothelial growth factor D. [provided by RefSeq]
Database
Research Area
